Marijuana (MJ): Medicinal or Malevolent?

Slides:



Advertisements
Similar presentations
E.4 Neurotransmitters and Synapses
Advertisements

Medical Marijuana A role in the Ataxias? Terry D. Fife, MD, FAAN Director, Balance Disorders & Otoneurology Barrow Neurological Institute Associate Professor.
The Medical Marijuana Maze Chapter One: Introduction Nancy E. Marion Copyright © 2014 Nancy Marion. All rights reserved.
Figure 3.16 Different Types of Synaptic Connections
Psych 181: Dr. Anagnostaras Lec 10: Marijuana. cannabinoids Marijuana and cannabinoids Cannabis sativa, hemp One of earliest non-food plants cultivated.
Marijuana and Teenage Psychosis David Ruffino Student Nurse. PPC Term Five.
Effects of Cannabanoids on the brain! Delta 9-THC.
Effect of Acute Marijuana on Cardiovascular Function and Central Nervous System in occasional and chronic marijuana users Rakesh Awasthi College of Pharmacy.
Marijuana and Your Lungs. What is Marijuana? Marijuana is the most widely used illegal drug in North America. It is a mixture of dry, shredded flowers,
Medical Marijuana: Risks and Benefits Malcolm P. Rogers, M.D. Portland VA Clinic malcolm.
Cannabis Sativa Leaves, flowers, stems, and seeds are smoked, combined with food, or brewed as tea Marijuana – dried leaves and flowers Hashish – concentrated,
JESSICA KAHN, MD MPH Marijuana and the Teen Brain.
#279 Cannabis For Symptom Control By: Kelsey Jungels.
Uncovering Cannabis Derek McNamara COM 100. Fun Fact Marijuana has never caused a single death from overdosing – it’s simply not possible!
Cannabinoids Overview: Medical Use, Abuse, Pharmacotherapy, and Assessment of Consequences Christian J. Teter, PharmD, BCPP Associate Professor, Psychopharmacology.
How and Why Drugs Work Chapter 5
© CAMS Trial 2001 CAMS Study A Multicentre Randomised Controlled Trial of Cannabinoids in Multiple Sclerosis Principle Investigators Dr John Zajicek Dr.
Drug Abuse Education Course Master Sgt. Doug Oswald Assistant Drug Demand Reduction Administrator.
Cannabinoid use in Cancer Patients PAS 646 Univ. of Kentucky Ryan Filiatreau.
Medical Cannabis in Maryland Presentation to University of Maryland Medical School Quarterly Meeting October 8, 2015 by Deborah Miran Commissioner Maryland.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Marijuana & Medication Assisted Treatment for OUD How can science inform agency policies? Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of.
Cannabis: The plants used for making marijuana Plant features Annual Dioecious Flowering Wind-pollinated.
Endocannabinoid signaling and stress in CVS Thangam Venkatesan, MD Associate Professor of Medicine Division of Gastroenterology and Hepatology Medical.
Pharmacology of Cannabis Emily Brown, Puranjay Mahajan, and Caylie Poirier 24 November 2015 PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
Does it have medical value?.  Marijuana is a hemp plant that grows in tropical and temperate climates.  2 types of marijuana. Cannabis sativa and Cannabis.
For Internal Use Only NBRC4Y
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Selected Effects on Brain, Body
Chapter 14 Opener State initiatives such as the 2012 Oregon Cannabis Tax Act are aimed at decriminalizing or even legalizing the possession and use of.
Cannabis and Schizophrenia. Major Constituents of Cannabis The two major substances found in cannabis include tetrahydrocannabinol (THC) and cannibidiol.
Cannabis: What's wrong with a joint? PRESENTED BY FRANCIS SPENCER After 20 years of research: Finally the truth about MARIJUANA.
Yesenia Santiago Engl  Marijuana is of leaves, stems, seeds and chopped dried flowers of the plant called Cannabis Sativa.  Common names: grass,
What is Marijuana? A dry shredded mix of flowers, seeds, and leaves of the Cannabis Sativa plant. Most commonly abused illegal drug which affects memory,
Psychoactive Plants Hallucinogens - I: Marijuana.
2017 Epidemiological Report
COMORBIDITY IN ADDICTION AND OTHER MENTAL ILLNESSES
Eucrisa™ - Crisaborole
What are the FACTS we all need to know?
Opioids Aware A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.
Pharmacology II Tutoring: Drugs of abuse & alcohol
The Central Nervous System
Medical Cannabis Dr. Andrea Burry MSc MD CCFP
The Yin and Yang of Cannabis
Adolescent Chemical Dependency
Properties of Cannabis
Is the most commonly used illicit drug in the United States
Treatment of Parkinson’s disease
CANNABIS AND CANNABINOIDS: THE CONUNDRUM
MEDICAL CANNABIS 101.
Drugs that activate Gio-proteins receptors
Pharmacokinetics & pharmacodynamcs
Introduction; Scope of Pharmacology Routes of Drug Administration
Marijuana and Your Lungs
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Clinical Pharmacokinetics
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Psychoactive Drugs Because the nervous system interacts with every other system of the body, dysfunction of any of its parts can have numerous effects.
Clinical Cannabis Interprofessional Education: Program Development and Provider Knowledge Cameron, M.H. 1,2 & Jones, K.D.3,4 1. VA Portland Health Care.
Drug Abuse Munir Gharaibeh, MD, PhD, MHPE
Introduction to Pharmacology
A Review of the Evidence for Medical Cannabis Based on Approved Conditions in Iowa Authors: Ryan Molander, Sarah Kadura, spencer smythe, and nickolas Scott.
PRECEPTOR: RONALD HERMAN
ADDICTION
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Introduction to Pharmacology
CBD & PREGNANCY When a woman becomes pregnant, everything she comes into contact with can potentially affect.
National Hospice and Palliative Care Organization’s Palliative Care Resource Series Cannabis Use in Palliative Care: History, Legality and Implications.
Neurological Aspects of THC as a Treatment for Generalized Anxiety
Presentation transcript:

Marijuana (MJ): Medicinal or Malevolent? Christian J. Teter, PharmD, BCPP Associate Professor, Psychopharmacology University of New England (UNE) College of Pharmacy & Center for Excellence in the Neurosciences Portland, ME cteter@une.edu

Disclosure Statement Dr. Teter reports no real or perceived financial relationships or other conflicts of interest Dr. Teter will be discussing ‘unapproved’ uses for cannabinoids (including cannabis, marijuana, etc.) PLEASE NOTE: the intended purpose of this lecture is to provide a brief overview of topics related to cannabinoids: References available upon request (cteter@une.edu) NIDA/SAMHSA materials are in the public domain

Marijuana: Medicinal or Malevolent? Learning Objectives: Describe the pharmacology and pharmacokinetics of cannabinoids Explore the currently known adverse effects and efficacy of cannabinoids

Cannabinoids (CB): Outline PART #1: CB Primer Categorization: PART #2: Potential Adverse Effects & Efficacy (selected from much larger literature) Endogenous vs. exogenous Natural vs. synthetic Pharmacodynamics (PD) National Academies Press (NAP) – **seminal report** Pharmacokinetics (PK) CB receptor system CNS regional effects

Part #1: Cannabinoid (CB) Primer

CB: Categorization Natural CBs Synthetic CBs Endogenous ligands Primary example: Anandamide Exogenous ligands (e.g., CB sativa, CB indica) ∆-9-tetrahydrocannabinol (THC) Synthetic CBs Prescription medications Dronabinol (Marinol); nabilone (Cesamet) Sativex (…not yet available in the U.S.) Recreational use “Spice/K2” (potent CB agonist formulations)

CB: Pharmacodynamics 60(+) CBs [note: not identical PD properties] MJ is a complex plant Numerous compounds 60(+) CBs [note: not identical PD properties] Various strains Differing CB concentrations Lack of correlation between drug concentrations and physiologic effect Highly variable drug administration Concerns with self-titration and dosing Borgelt et al. Pharmacotherapy (2013)

NOTE: Delay has contributed to AEs CB: Pharmacokinetics THC Half-life = 30 hours (wide variability) Smoked THC Absorption: rapid (within minutes) Bioavailability: wide range (10-25%) Oral THC Absorption: variable Peak concentrations: 1-3 hours Other formulations: vaporized Teter CJ: [Variability (PD) x Variability (PK)] = [Variability] (i.e. lack PK/PD standardization) NOTE: Delay has contributed to AEs Borgelt et al. Pharmacotherapy (2013)

Biological Underpinnings ENDOGENOUS CB SYSTEM: Retrograde neurotransmission See diagram Modulates neurotransmitter activity (e.g., glutamate) Multitude of CNS effects Diverse CB receptor density throughout the brain Image source: NIDA-Scholastic

CB: Endocannabinoid System CB1 Receptors CNS: Basal Ganglia, Cerebellum, Hippocampus, Hypothalamus, Limbic system, Neocortex G-protein activity Signal transduction pathways Neuronal stabilization CNS “dampening” effect CB1 binding induces dopamine activity CB2 Receptors Periphery: immune cells and tissue CB2 binding effects in CNS not well-understood EFFICACY PERHAPS?? Bloomfield et al. Biol Psychiatry (2014); Borgelt et al. Pharmacotherapy (2013); Rodríguez de Fonseca et al. Alcohol Alcoholism (2004); www.cnsforum.com

CB: THC Binding Sites Source (public domain): National Institute on Drug Abuse (NIDA)

Source (public domain): National Institute on Drug Abuse (NIDA)

Part #2: Available at: https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state

NASEM: Weight of Evidence Conclusive Substantial Moderate Limited No/Insufficient Focus of this lecture

NASEM: Box 11-1, page 11-7

Conclusive/Substantial Evidence Efficacy findings: Cannabis: chronic pain in adults Localization in pain ‘centers’ (e.g., CNS and spinal cord) MOA: topic of ongoing investigation Lack of evidence in the United States Please see NASEM Report excerpt on following slide Oral cannabinoids: nausea & vomiting (chemotherapy) Oral cannabinoids: patient reported spasticity symptoms (multiple sclerosis) NASEM Report (2017)

NASEM Report (excerpt) “very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States. Given the ubiquitous availability of cannabis products in much of the nation, more research is needed on the various forms, routes of administration, and combination of cannabinoids.” NASEM Report (2017)

Conclusive/Substantial Evidence Adverse health effects: Smoking cannabis: bronchitis episodes Maternal cannabis: lower birth weight in offspring Cannabinoids: motor vehicle accidents How are we going to monitor this situation?? Teter CJ. Drugged Driving. Journal Tribune 2016/2017 Pharmacokinetic/Pharmacodynamic issues QUESTION(S) FOR THE AUDIENCE: what concrete information does a given blood concentration of THC provide? For example, is driving with THC 5 ng/mL in your bloodstream safe for you and other drivers? NASEM Report (2017)

Marijuana vs. Alcohol (monitoring example) Image source: BACtrack

Conclusive/Substantial Evidence Adverse mental health effects: Cannabinoids: psychoses/schizophrenia Frequency of CB use Longitudinal outcomes: Conversion to psychosis Causality?? Dose-response Temporal relationships Biological plausibility Example: D2R2 polymorphism rs1076560 GG vs. T carriers NASEM Report (2017)

Conclusive/Substantial Evidence Substance use behaviors: Problem cannabinoid use Risk factors: Male and smoking cigarettes Frequency of CB use Early age of initiation Non-risk factors: ADHD treatment with stimulant medication Is cigarette smoking the true “gateway” drug?? NASEM Report (2017)

CB: Addiction (risk) Research has demonstrated: Approximately 9% of those who use marijuana may become addicted. Rate increases to 17%, for those who start in their teens. Up to 25–50% among daily users. Lopez-Quintero et al (2011); Volkow et al. NEJM (2014) Image source: NIDA (public domain)

Next Steps/Future Directions

UNE K-12 Educational Outreach Provide facts and information Not an intervention Interactive activities (e.g., 2-D poster + 3-D brain model Collecting data on whether these educational outreach activities produce any positive outcomes

Question & Answer Session